Alto Neuroscience investors sue over alleged securities fraud in IPO.

Levi & Korsinsky has filed a class action lawsuit on behalf of Alto Neuroscience investors who purchased the company's stock between February 2, 2024, and October 22, 2024. The lawsuit alleges securities fraud and seeks to recover losses for affected investors. Those who purchased Alto common stock during this period may be eligible to participate in the lawsuit.

New York, NY / September 12, 2025 - Levi & Korsinsky has filed a class action lawsuit on behalf of investors who purchased Alto Neuroscience Inc. (NYSE: ANRO) stock between February 2, 2024, and October 22, 2024. The lawsuit alleges securities fraud and seeks to recover losses for affected investors.

The complaint alleges that Alto Neuroscience made materially false and misleading statements concerning the clinical, regulatory, and commercial prospects of ALTO-100, a drug developed for the treatment of major depressive disorder. The lawsuit claims that the company overstated the effectiveness of ALTO-100, leading investors to believe that the drug was more effective than it actually was. As a result, the company's business and financial prospects were also overstated.

Investors who purchased Alto common stock during the specified period may be eligible to participate in the lawsuit. The deadline to request appointment as lead plaintiff is September 19, 2025. Those interested can visit the firm's website or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Alto Neuroscience, Inc. (NYSE: ANRO)^[1].

Levi & Korsinsky, a well-known law firm specializing in securities fraud class actions, has a track record of recovering millions of dollars for investors. The firm has been recognized for its success in representing investors in complex litigation.